Gasnil

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gasnil

Property Description
Active ingredient Simethicone (Simeticone)
Form Oral Suspension, Tablets, Capsules, Drops
Pharmacological class Antiflatulent
Common use Relief of gas-related discomfort (bloating, trapped wind)
Origin Synthetic (Silicon-based compound)

What Type of Medicine is Gasnil?

Gasnil is an over-the-counter (OTC) medicinal product containing the active substance Simethicone (INN: Simeticone), which is formally classified as an Antiflatulent agent. Its primary, general purpose is to provide effective relief from the symptoms associated with excess gas in the gastrointestinal tract, including bloating, pressure, and the pain of trapped wind. The medicine's efficacy in addressing symptoms of functional gastric bloating is clinically recognized.

Simethicone's function is rooted in a physical process; it acts as a non-systemic surfactant (antifoaming agent). Unlike systemically absorbed drugs or antacids, Simethicone alters the surface tension of gas bubbles within the gut, causing them to coalesce (merge). This action facilitates the natural expulsion of gas through belching or flatulence.


Simethicone: Composition and Origin and Forms

The active ingredient, Simethicone, is a synthetic, silicon-based compound chemically composed of polydimethylsiloxanes and silica gel. This composition ensures its non-toxic, inert nature, meaning it is not metabolized or absorbed into the bloodstream, acting only locally. The product is often sold as a single-ingredient medicine but is also available as a combination product, frequently including antacids to treat concurrent symptoms of both gas and indigestion.

Gasnil is intended for oral administration and is supplied in various dosage forms, such as oral suspension (liquid/drops), tablets, capsules, and chewable films. The availability of these forms ensures suitability for a broad target audience, including adults, children, and infants.

What side effects are possible with Gasnil?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety information for Gasnil as officially documented in government regulatory sources, such as Prescribing Information and Summary of Product Characteristics (SmPC). This information is grouped by frequency and body system to provide a clear regulatory understanding of the medicine’s risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the frequency observed in clinical studies and documented in the official labeling. Categories include Very Common (occurring in 1 in 10 or more patients), Common (1 in 100 to less than 1 in 10), Uncommon (1 in 1,000 to less than 1 in 100), Rare, and Very Rare. All documented side effects are organized by System-Organ-Class (SOC), such as those affecting the Nervous system, Gastrointestinal tract, or Skin and subcutaneous tissue.

Serious Adverse Reactions

Specific adverse events that regulatory authorities deem critical due to their severity are highlighted. These typically include serious reactions such as documented Anaphylactic reaction, severe Hepatotoxicity (liver damage), and certain Severe Cutaneous Adverse Reactions (SCARs).

Safety-Related Restrictions and Considerations

Official labeling defines restrictions on the use of Gasnil. It is contraindicated in patients with a known history of severe hypersensitivity to the product. Furthermore, regulatory documents may state limitations for specific populations, such as use during pregnancy and breastfeeding or in patients with defined renal or hepatic impairment. The safety profile also includes mandatory requirements for specific monitoring during therapy, which may include laboratory or cardiac assessments.

Time- or duration-related safety patterns, such as the risk of a specific withdrawal syndrome upon abrupt cessation, are documented when explicitly established by regulatory review.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Gasnil (Simethicone) overdose is directly defined by the active ingredient's pharmacological properties. Simethicone is a non-systemically absorbed compound; therefore, regulatory documents state that systemic toxicity is not anticipated following over-ingestion. This profile means that specific overdose manifestations affecting physiological systems, such as the heart or kidneys, are not documented in official labeling, and severe or life-threatening outcomes are not expected as a direct result.

Required Emergency Actions

Official guidance requires specific steps in the event of any suspected over-ingestion of the medication:

  • Seek immediate medical attention for the suspected overdose event.
  • The use of Gasnil must be discontinued immediately.

The regulatory basis for Simethicone confirms that no specific antidote is known or required for its overdose. Management is limited to symptomatic and supportive treatment. Furthermore, regulatory labeling does not detail population-specific overdose notes regarding increased severity for the elderly or those with underlying hepatic or renal conditions, given the drug's inert nature. All cases of over-ingestion must be reported to a healthcare professional for appropriate evaluation.

Therapeutic Uses of Gasnil

What Gasnil Treats: Main Uses and Benefits

Gasnil (simethicone) is an over-the-counter (OTC) medication commonly used to help with symptoms related to systemic imbalance in the gastrointestinal tract. Its primary therapeutic domain is applied in addressing symptom clusters that may become intense or disruptive, such as uncomfortable or painful pressure, a feeling of fullness, and bloating.

Simethicone is relevant for easing symptoms that interfere with daily comfort. It is often used across conditions presenting with acute episodes of gas-related discomfort. These scenarios involve heightened symptoms where supportive relief is needed.

The medication contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability. It is generally part of symptomatic management when short-term symptomatic assistance is needed. This product supports the patient during episodes of heightened discomfort by easing distress.


Quick Fact: It may assist with easing symptoms related to physical discomfort like pressure and bloating.


Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gasnil (Simeticone) — Official Regulatory Information

This section describes the official population eligibility and exclusion criteria for the medicine based strictly on governmental regulatory documents.


Eligibility Scope

Scope Regulatory Statement (based on Simeticone)
Populations for whom use is allowed (as stated in label): Adults and adolescents (from the age of 15 years and over), in formulations intended for this age group.
Populations for whom use is not recommended (if applicable): Infants and children (under the age of 15 years) in certain adult-focused formulations, often due to limited safety data established for that specific product.
Populations for whom use is contraindicated: Individuals with known hypersensitivity to the active substance simeticone or to any of the product's excipients.
Age-related eligibility rules: Use is generally reserved for adults and adolescents (age 15+). Formulations specifically for infants and children may have different, established age limits.
Condition-specific eligibility rules: No specific dosage adjustment is required for patients with renal or hepatic impairment due to the drug's lack of systemic absorption.
Pregnancy and lactation eligibility status: Can be used during pregnancy and breastfeeding. As the drug is not systemically absorbed, negligible to no effect is anticipated on the foetus or breastfed infant.

Eligibility Classifications (High-Level)

Classification Regulatory Statement
Eligibility severity classification: Contraindicated (Hypersensitivity); Not Recommended (Certain pediatric groups in some adult-focused formulations).
Regulatory basis: EMA Summary of Product Characteristics, FDA-recognized monographs, and other government drug authorities.

Connection to the Overall Eligibility Profile

The medicine's eligibility is determined primarily by two factors: the absolute contraindication for individuals with hypersensitivity to any component, and an age restriction that reserves use for adolescents and adults in most standard preparations. Due to its unique, non-systemic action, the medicine is typically permitted for use during pregnancy and breastfeeding, as regulatory documents state that no systemic exposure is expected.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Gasnil (Simethicone) is uniquely narrow due to its non-systemic nature. Because the active ingredient is not absorbed into the bloodstream or metabolized by the body, Gasnil does not participate in the systemic pathways that typically cause significant drug-drug interactions. Consequently, official regulatory documentation confirms the absence of interactions involving major enzyme systems, such as the cytochrome P450 (CYP) enzymes, and transport proteins.

Clinically Significant Interaction and Timing Separation

One officially documented interaction is the potential for Simethicone to interfere with the absorption of Levothyroxine (a thyroid medication). This is classified as a clinically significant interaction because the physical presence of Gasnil in the gastrointestinal tract can reduce the oral bioavailability, and thus the plasma concentration, of Levothyroxine.

To mitigate this effect, a mandatory timing rule is required by regulatory authorities: Simethicone must be administered at least four hours apart from Levothyroxine.

Other Substances

No interactions with food, alcohol, or specific herbal products are officially documented in regulatory information. There are no formally classified contraindicated combinations listed for Simethicone.

Mechanism of Action

Physical Mechanism: Surface Tension Modulation

Gasnil, containing Simethicone, operates through a unique, physical, non-systemic mechanism entirely confined to the gastrointestinal lumen. The compound functions as a surfactant by rapidly reducing the surface tension of the liquid films that stabilize small gas bubbles and foam within the gut. This physical action defines the mechanical domain of the compound, targeting the gas-liquid interface rather than biological tissue.


Gastrointestinal Gas State Alteration

The destabilization of the foam structure initiates a mechanistic cascade where the numerous small gas bubbles coalesce (merge) into much larger, free gas pockets. This physical Gas State Alteration results in large, free gas pockets that are subject to natural expulsion through belching or flatulence. Since Simethicone is non-absorbable, the effect is limited to the gut and results in the attenuation of pressure on the bowel wall.


️ Mechanistic Constraints

This antifoaming mechanism is strictly relevant for gas trapped by foam and does not influence the biological processes that create gas, such as bacterial fermentation. The mechanism is constrained when gas is trapped by a physical obstruction or when gas generation, rather than entrapment, is the dominant physiological factor.

Dosage and Administration Information

How to Use Gasnil (Simethicone)

Gasnil, containing the active ingredient Simethicone, is administered exclusively via the oral route for over-the-counter use. The medication is generally taken as needed (PRN), with a standardized schedule of up to four times daily.

Dosing and Frequency

Administration should be timed to occur after meals and at bedtime. Dosing is based on the age of the patient, and the maximum daily amount must not be exceeded.

Age Group Standard Single Dose (As Needed) Maximum Daily Dose (24 Hours)
Infants (<2 yrs) 20 mg (liquid drop form) 240 mg
Children (2-12 yrs) 40 mg 480 mg
Adults (12+ yrs) 40 mg to 125 mg 500 mg

Administration and Preparation

Procedural rules must be followed for effective use of the specific dosage form:

  • Oral Liquid/Drops: The bottle must be shaken well before each dose. The dose must be measured precisely using the calibrated dropper or dosing cup provided.
  • Infant Drops: The drops may be given directly or mixed with water, formula, or other liquids.
  • Chewable Tablets: These must be chewed thoroughly before being swallowed whole, as directed by the product label.
  • Capsules: Regular or liquid-filled capsules must be swallowed whole.

If the medication is taken on a regular schedule and a dose is missed, it is generally recommended to skip the missed dose and continue the regular schedule, rather than taking a double dose. Simethicone should not be used parenterally (by injection) or via inhalation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gasnil (Simethicone)


Evidence for the Relief of Gas-Related Discomfort

Research has examined Gasnil (Simethicone) primarily in short-term Randomized Controlled Trials (RCTs). These trials were applied in studies examining patient-reported experiences of adults who were experiencing conditions involving periods of heightened symptoms, such as bloating, a feeling of pressure, and abdominal pain related to excess gas. The study outcomes monitored these patient-reported outcomes describing perceived discomfort over defined, limited time intervals.

Findings describe patterns observed in the studies over the study period related to these outcomes. However, the findings have been mixed. While some trials reported measurements of change, others report how symptoms evolved in the observed populations that did not consistently separate from the patterns seen in the placebo group. The evidence quality varies across studies when assessing overall symptom improvement.


Research on Gasnil's Use in Diagnostic Procedures

Research has also explored the use of Simethicone in contexts beyond treating discomfort. Prospective RCTs were conducted to evaluate Gasnil as an adjunct preparation for patients undergoing endoscopic procedures like colonoscopy. Research explored whether the addition of Simethicone to standard preparation was followed by measurements showing a reduction of foam and air bubbles that may interfere with the doctor's view.

These findings describe patterns observed in the studies where the addition of the product was followed by measured differences in the visualization of the intestinal lining. Uncertainty here relates to the variability of findings, particularly regarding whether adding Simethicone consistently affects the overall quality of bowel preparation across all regimens.


Research in Infantile Populations

Gasnil was evaluated in specific research contexts involving infants who met the criteria for infantile colic. Studies used placebo-controlled RCTs to assess changes in crying duration and crying frequency. High-level systematic reviews contribute to understanding that outcomes did not consistently separate from the placebo control observed in these infants. Consequently, certainty remains low in the evidence base regarding the product's role in this population.

Key Studies & References

  1. Simethicone - StatPearls - NCBI Bookshelf
  2. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines | BMJ Open

Frequently Asked Questions (FAQ)

Common questions about Gasnil (FAQ)


Q: How quickly should I expect Gasnil to start working?

Gasnil (Simethicone) acts locally in the digestive tract by reducing the surface tension of gas bubbles. Its physical action suggests the effect may be rapid, as it does not rely on systemic absorption. However, official product information does not consistently define a specific time frame for symptom relief.


Q: How long does the effect of Gasnil typically last?

Since Gasnil is not absorbed into the bloodstream, its action is confined to the gut where it assists in the expulsion of trapped gas. Due to this non-systemic mechanism, the duration of the effect is expected to be short, aligning with its use as an 'as needed' medication.


Q: Can Gasnil cause constipation or diarrhea?

Regulatory documents indicate that gastrointestinal events, including constipation and diarrhea, have been reported as adverse reactions. These effects are generally classified as uncommon or rare based on observations from clinical and post-marketing settings.


Q: Is it normal to feel a bit drowsy after taking Gasnil?

Adverse events affecting the nervous system, such as somnolence (drowsiness) and dizziness, have been reported, though these are typically uncommon or rare according to official safety documentation. If any adverse effects, including drowsiness, are experienced, it is recommended to consult a healthcare provider.


Q: Is there a version of Gasnil specifically for children?

Yes, Simethicone, the active ingredient in Gasnil, is available in specific liquid drop formulations. These products come with dosing instructions that are tailored and approved for use in infants and children, typically those under 2 years of age.


Q: What happens if I accidentally miss a dose of Gasnil?

As Gasnil is intended for 'as needed' relief of active gas symptoms, regulatory instructions generally advise against compensating for a missed dose. Individuals should continue to take the medication only when needed for symptoms, without taking an extra dose.


Q: What is the maximum number of days I can continuously use Gasnil?

Official labeling specifies a maximum daily dose that should not be exceeded in a single 24-hour period. However, a universal limit for the number of continuous days is not defined. For symptoms that persist, it is appropriate to consult a healthcare provider.


Q: Can Gasnil be used for persistent bloating and gas?

Gasnil is officially indicated for the relief of symptoms related to excess gas, including bloating and pressure. For symptoms that are chronic or persistent, individuals should seek the guidance of a healthcare provider for proper diagnosis and care.


Q: Do I need to take Gasnil regularly, or only when symptoms occur?

The official directions for use state that Gasnil is intended to be taken 'as needed' (PRN) when symptoms of gas, pressure, or bloating are present. It is not generally formulated or labeled to be taken on a scheduled, continuous basis.


Q: Can Gasnil make you feel dizzy?

Dizziness has been reported as a rare side effect in official safety documentation. It may also be associated with serious allergic reactions, and any severe or concerning symptoms should prompt consultation with a healthcare professional.


Q: What should I look for on the label when buying Gasnil?

When purchasing Gasnil, it is important to check the active ingredient, which is Simethicone, and verify its strength in milligrams (mg). The label should also list the approved uses (such as relieving gas and bloating), warnings, and directions for administration.


Q: What are the signs that Gasnil is actually working?

Gasnil is intended to relieve symptoms of discomfort, pressure, and bloating caused by trapped gas. The intended outcome of its physical action is the relief of these symptoms by facilitating the natural passing of gas.


Q: Can Gasnil cause changes in my stool or urine?

Simethicone may be associated with gastrointestinal changes like constipation or diarrhea. Urinary retention has been noted as a very rare adverse event. However, changes in the color or general appearance of stool or urine are not typically listed in the official safety information.


Q: What is the shelf life of Gasnil?

The shelf life of Gasnil is determined by the specific expiration date that is clearly printed on the product's packaging. It is important to adhere to this date and to dispose of any expired medication according to regulatory disposal guidelines.

How should Gasnil be stored and disposed of?

How to Store and Dispose of Gasnil?

The official storage and disposal guidelines for Gasnil (simethicone) are documented to maintain product stability and ensure public safety.


Storage Requirements

Condition Requirement
Temperature Store at room temperature.
Protection Keep away from excess heat and moisture (do not store in a bathroom).
Container Keep in the original container, tightly closed, with safety caps locked.
Child Safety Must be kept out of the sight and reach of children (place in an up-and-away location).

️ Disposal Instructions

Regulatory authorities advise discarding unused or expired Gasnil preferably through a medicine take-back program. The medication must not be flushed down the toilet. If a take-back option is unavailable, unwanted medicine should be mixed with an undesirable substance (like coffee grounds), sealed in a bag or container, and placed in the household trash. Always scratch out all personal information on the packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gasnil found in:

A-Z Index: